MNOV

MediciNova Inc

MNOV, USA

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

https://medicinova.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
MNOV
stock
MNOV

MediciNova (NASDAQ:MNOV) Receives “Buy” Rating from D. Boral Capital Defense World

Read more →
MNOV
stock
MNOV

D. Boral Capital Maintains MediciNova (MNOV) Buy Recommendation Nasdaq

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$7

Analyst Picks

Strong Buy

2

Buy

0

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Low

1.72

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-6.94 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-6.41 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-1,383.49 %

Low 5%

High 15%

Debt to Equity

-

Very High

0.08

Low 1

High 0.3

Investors

* Institutions hold a combined 13.67% of the total shares of MediciNova Inc

1.

Essex Woodlands Health Ventures

(2.2549%)

since

2025/06/30

2.

BlackRock Inc

(1.4185%)

since

2025/06/30

3.

Vanguard Group Inc

(1.3999%)

since

2025/06/30

4.

Citigroup Inc

(1.2069%)

since

2025/06/30

5.

Geode Capital Management, LLC

(1.0722%)

since

2025/06/30

6.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9398%)

since

2025/07/31

7.

Fidelity Extended Market Index

(0.543%)

since

2025/07/31

8.

Susquehanna International Group, LLP

(0.5104%)

since

2025/06/30

9.

UBS Group AG

(0.453%)

since

2025/06/30

10.

Renaissance Technologies Corp

(0.3644%)

since

2025/06/30

11.

State Street Corp

(0.356%)

since

2025/06/30

12.

Northern Trust Corp

(0.2849%)

since

2025/06/30

13.

Barclays PLC

(0.2202%)

since

2025/06/30

14.

iShares Micro-Cap ETF

(0.2105%)

since

2025/08/31

15.

Bank of New York Mellon Corp

(0.1961%)

since

2025/06/30

16.

Bank of America Corp

(0.1926%)

since

2025/06/30

17.

Fidelity Total Market Index

(0.18%)

since

2025/07/31

18.

Extended Equity Market Fund K

(0.1653%)

since

2025/06/30

19.

Bridgeway Capital Management, LLC

(0.155%)

since

2025/06/30

20.

Charles Schwab Investment Management Inc

(0.1458%)

since

2025/06/30

21.

Schwab Total Stock Market Index

(0.1458%)

since

2025/07/31

22.

Bridgeway Ultra-Small Company Market

(0.1432%)

since

2025/06/30

23.

Dimensional Fund Advisors, Inc.

(0.135%)

since

2025/06/30

24.

Fidelity Series Total Market Index

(0.1328%)

since

2025/07/31

25.

Spartan Extended Market Index Pool F

(0.1127%)

since

2025/07/31

26.

SBI Securities Co Ltd

(0.0886%)

since

2025/06/30

27.

NT Ext Equity Mkt Idx Fd - L

(0.0854%)

since

2025/06/30

28.

Northern Trust Extended Eq Market Idx

(0.0854%)

since

2025/06/30

29.

NT Ext Equity Mkt Idx Fd - NL

(0.0749%)

since

2025/06/30

30.

Schonfeld Strategic Advisors LLC

(0.0709%)

since

2025/06/30

31.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0582%)

since

2025/06/30

32.

Fidelity Nasdaq Composite Index

(0.0529%)

since

2025/07/31

33.

Spartan Total Market Index Pool G

(0.0521%)

since

2025/07/31

34.

Vanguard U.S. Eq Idx £ Acc

(0.0318%)

since

2025/07/31

35.

Northern Small Cap Core I

(0.0316%)

since

2025/06/30

36.

Dimensional US Core Equity 2 ETF

(0.0295%)

since

2025/08/29

37.

Dimensional Global Core Equity USD Acc

(0.0251%)

since

2025/06/30

38.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0241%)

since

2025/06/30

39.

Hantz Financial Services, INC.

(0.0088%)

since

2025/06/30

40.

Tower Research Capital LLC

(0.0071%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

-0.06

EPS Estimate

-17.68

EPS Difference

17.62

Surprise Percent

99.6606%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(2.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.